Trials / Not Yet Recruiting
Not Yet RecruitingNCT06644495
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to evaluate the safety and efficacy of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with Iruplinalkib or planned to receive Iruplinalkib treatment in real-world clinical practice.
Conditions
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2027-04-30
- Completion
- 2027-04-30
- First posted
- 2024-10-16
- Last updated
- 2024-10-16
Source: ClinicalTrials.gov record NCT06644495. Inclusion in this directory is not an endorsement.